InflaRx N.V.
Research InflaRx N.V. (IFRX) on Bullrun: market cap USD 235.79M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerIFRX
- ExchangeNASDAQ
- CountryGermany
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 235.79M
- Financial periodQ2 2026
- RevenueEUR 0
- Net income-EUR 10.65M
- Free cash flow-EUR 2.61M
Valuation Snapshot
latest market cap is USD 235.79M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | EUR 29.33K | -EUR 45.63M | -EUR 35.43M | -24677.9% | -0.68 | EUR 16.02M | EUR 897.92K | EUR 41.56M |
| FY2024 | EUR 165.79K | -EUR 46.06M | -EUR 48.60M | -1900.8% | -0.78 | EUR 18.38M | EUR 805.09K | EUR 61.42M |
| FY2023 | EUR 63.09K | -EUR 42.67M | -EUR 37.89M | -743.7% | -0.78 | EUR 12.77M | EUR 1.12M | EUR 102.58M |
| FY2022 | EUR 0 | -EUR 29.48M | -EUR 33.91M | n/a | -0.67 | EUR 16.27M | EUR 1.36M | EUR 88.35M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-09 | USD 235.79M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 73.02M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 146.60M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 95.98M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 137.03M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 210.41M | n/a | n/a | n/a |
About InflaRx N.V.
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator to treat variety of autoimmune and other inflammatory diseases.
Related stock research
Other Healthcare stocks
TME PHARM.CONF.IPO EO 1- (0N6A)
Novogenia AG (7V0.DE)
TME Pharma N.V. (ALTME)
BioNTech SE (BNTX)
CO.DON AG INH. O.N. (CNW)
Formycon AG (FYB)
Heidelberg Pharma AG (HPHA)
Immatics N.V (IMTX)
PENTIXAPHARM HOLDING N AG (PTP)
bioXXmed AG (T5O.F)
Vivoryon Therapeutics NV (VVY)
SCHOTT Pharma AG & Co. KGaA (1SXP)
Frequently asked questions
What is InflaRx N.V.'s market cap?
InflaRx N.V.'s market capitalization is USD 235.79M.
What does InflaRx N.V. do?
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator to treat variety of autoimmune and other inflammatory diseases.